<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132155</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.031</org_study_id>
    <nct_id>NCT03132155</nct_id>
  </id_info>
  <brief_title>QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma</brief_title>
  <official_title>A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NantPharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NantPharma, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study that will assess the efficacy of AMG 337 in subjects with advanced or&#xD;
      metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase 2 single arm study will assess efficacy of AMG 337 (based on confirmed ORR) in&#xD;
      subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene&#xD;
      fusion, as determined by fluorescent in situ hybridization (FISH) or other diagnostic methods&#xD;
      and confirmed by RNA sequencing (RNAseq).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>Confirmed ORR (confirmed complete response or partial response) will be evaluated in accordance with RECIST Version 1.1 by BICR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the safety of AMG 337 based on grade 3 or 4 non-hematologic toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>To determine PFS, evaluated in accordance with RECIST Version 1.1 BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>To determine OS, defined as the time from the date of the first administration of therapy to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>To determine DOR, measured by RECIST Version 1.1 by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>4 months</time_frame>
    <description>To determine DCR (confirmed CR, PR, or SD) lasting for at least 4 months by BICR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Clear Cell Sarcoma</condition>
  <arm_group>
    <arm_group_label>AMG 337</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 337</intervention_name>
    <description>6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)</description>
    <arm_group_label>AMG 337</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.&#xD;
&#xD;
          2. Able to attend required study visits and return for adequate follow-up, as required by&#xD;
             this protocol.&#xD;
&#xD;
          3. Able to self-administer AMG 337 as a whole capsule by mouth every day.&#xD;
&#xD;
          4. Age ≥ 16 years.&#xD;
&#xD;
          5. Histologically confirmed, unresectable, locally advanced or metastatic tumors that&#xD;
             contain the EWSR1-ATF1 gene fusion, as determined by fluorescent in situ hybridization&#xD;
             (FISH) or other diagnostic methods and confirmed by RNA sequencing (RNAseq).&#xD;
&#xD;
          6. Have measurable disease evaluable in accordance with RECIST Version 1.1.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          8. Must have a recent Formalin-fixed paraffin-embedded (FFPE) tumor biopsy specimen that&#xD;
             was obtained following the conclusion of the most recent anticancer treatment. If an&#xD;
             historic specimen is not available, the subject must be willing to undergo a biopsy&#xD;
             during the screening period.&#xD;
&#xD;
          9. Must be willing to undergo a biopsy during the treatment period, if considered safe by&#xD;
             the investigator.&#xD;
&#xD;
         10. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
         11. Hematologic function, as follows:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.&#xD;
&#xD;
               2. Platelet count ≥ 50 × 109/L.&#xD;
&#xD;
               3. Hemoglobin &gt; 8 g/dL.&#xD;
&#xD;
               4. Prothrombin time (PT) or partial thromboplastin time (PTT) &lt; 1.5 × upper limit of&#xD;
                  normal (ULN), except for subjects on anticoagulation therapy for venous&#xD;
                  thromboembolism.&#xD;
&#xD;
         12. Renal function, as follows:&#xD;
&#xD;
             a. Calculated creatinine clearance &gt; 30 mL/min.&#xD;
&#xD;
         13. Hepatic function, as follows:&#xD;
&#xD;
               1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 × ULN&#xD;
                  and total bilirubin &lt; 1.5 × ULN.&#xD;
&#xD;
               2. Alkaline phosphatase (ALP) &lt; 2 × ULN (≤ 5 × ULN if bone or liver metastases are&#xD;
                  present)&#xD;
&#xD;
         14. Agreement to practice effective contraception (both male and female subjects, if the&#xD;
             risk of conception exists).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Assessed by the investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
          2. Inability to attend required study visits and return for adequate follow-up, as&#xD;
             required for this protocol.&#xD;
&#xD;
          3. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
          4. Women who are nursing, pregnant, or planning to become pregnant during the duration of&#xD;
             the study.&#xD;
&#xD;
          5. Current diagnosis or history of a second neoplasm, except the following:&#xD;
&#xD;
             a. Adequately treated non-melanoma skin cancer, curatively treated in situ disease, or&#xD;
             other solid tumors curatively treated with no evidence of disease for ≥ 2 years.&#xD;
&#xD;
          6. History of bleeding diathesis.&#xD;
&#xD;
          7. Uncontrolled hypertension (systolic &gt; 160 mmHg and/or diastolic &gt; 100 mmHg) or&#xD;
             clinically significant cardiovascular disease, cerebrovascular accident/stroke, or&#xD;
             myocardial infarction within 6 months before study day 1; unstable angina; congestive&#xD;
             heart failure of New York Heart Association grade 2 or higher; or serious cardiac&#xD;
             arrhythmia requiring medication.&#xD;
&#xD;
          8. Baseline ECG Fridericia's formula QTcF &gt; 470 ms.&#xD;
&#xD;
          9. Active infection requiring intravenous (IV) antibiotics within 2 weeks before study&#xD;
             day 1.&#xD;
&#xD;
         10. Significant gastrointestinal disorder (eg, Crohn's disease, ulcerative colitis,&#xD;
             extensive gastrointestinal resection) that in the opinion of the Investigator may&#xD;
             influence drug absorption.&#xD;
&#xD;
         11. Positive result of screening test for human immunodeficiency virus (HIV).&#xD;
&#xD;
         12. Evidence of acute hepatitis B and C. Subjects with chronic hepatitis B or C are&#xD;
             eligible if their condition is stable and, in the opinion of the investigator, would&#xD;
             not pose a risk to subject safety.&#xD;
&#xD;
         13. Toxicities from prior anti-tumor therapy not resolved to CTCAE Version 4.03 grade 0 or&#xD;
             1.&#xD;
&#xD;
             a. Grade 2 toxicities from prior anti-tumor therapy that are considered irreversible&#xD;
             (defined as having been present or stable for &gt; 4 weeks), such as stable grade 2&#xD;
             peripheral neuropathy or ifosfamide-related proteinuria, may be allowed if they are&#xD;
             not otherwise described in the exclusion criteria.&#xD;
&#xD;
         14. Participation in this study or in an investigational study and/or procedure with any&#xD;
             molecularly targeted agents reported to inhibit Mesenchymal epithelial transition&#xD;
             factor (MET) within 14 days before study day 1.&#xD;
&#xD;
         15. Anti-tumor therapy, including chemotherapy, antibody therapy, retinoid therapy, or&#xD;
             other investigational therapy within 14 days before study day 1.&#xD;
&#xD;
         16. Therapeutic or palliative radiation therapy within 14 days before study day 1.&#xD;
&#xD;
         17. Major surgery within 28 days before study day 1.&#xD;
&#xD;
         18. Any comorbidity that in the opinion of the investigator may increase the risk of&#xD;
             toxicity.&#xD;
&#xD;
         19. Concurrent or prior use of a strong CYP3A4 inhibitor within 14 days before study day&#xD;
             1, including the following: ketoconazole, itraconazole, clarithromycin, indinavir,&#xD;
             nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole.&#xD;
&#xD;
         20. Concurrent or prior ingestion of grapefruit or grapefruit products, or other foods&#xD;
             known to inhibit CYP3A4 within 7 days before study day 1.&#xD;
&#xD;
         21. Concurrent or prior use of strong CYP3A4 inducers within 28 days before study day 1,&#xD;
             including the following: phenytoin, carbamazepine, rifampin, rifabutin, rifapentin,&#xD;
             phenobarbital, or the herbal supplement St. John's Wort.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Clear Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

